PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(01): 062-067
DOI: 10.1055/s-0042-1753477
Original Article
Breast Cancer

Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer

Sonia Dhaka
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
*   Equal Contribution
,
Rupal Tripathi
2   Department of Research, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
*   Equal Contribution
,
Dinesh Chandra Doval
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
,
Anurag Mehta
3   Department of Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
,
Udip Maheshwari 
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
,
Venkata Pradeep Babu Koyyala
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
,
Jatinderpal Singh
4   Department of Gastroenterology, SGHS Super Speciality Hospital, Mohali, Punjab, India
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Zoom
Dinesh Chandra Doval

Background Circulating tumor cells (CTCs) in the peripheral blood may play a major role in the metastatic spread of breast cancer. This study was conducted to assess the role of CTCs to determine the prognosis in terms of survival in metastatic breast cancer patients.

Methods This prospective study of 36 patients was conducted at the Hospital from April 2016 to May 2018. Details of each patient related to the demographic profile, tumor type, treatment, and follow-up information were recorded. The number of CTCs in the peripheral blood was measured by Celsee PREP 400 sample processing system and Celsee Analyzer imaging station.

Results There was a positive correlation between the number of site of metastasis with number of CTCs (p-value < 0.001). In the patients with clinical/partial response, a significant reduction in the number of CTCs after 1 month of therapy was observed (p-value = 0.003). When the number of CTCs at baseline and 6 months were compared with the positron emission tomography response at 6 months, a statistically significant difference in CTCs in patients having partial response after 6 months was observed (p-value = 0.001). On comparison with the responder groups, a statistically significant reduction in CTCs at baseline and 6 months was observed (p-value = 0.001). Patients with CTCs less than 5 and more than or equal to 5 after 1 month of treatment had a mean progression-free survival of 11.1 months and 7.5 months (p-value = 0.04) and a mean overall survival of 11.6 and 9.6 months (p-value = 0.08), respectively.

Conclusion Assessment of CTCs provides a more quantifiable response than radiographic evaluation and at a much earlier time point and is also a better predictor of survival.

Keywords

circulating tumor cells - metastatic breast cancer - response - survival - prognosis

Ethical Approval

This study was approved by the Institutional Review Board.


Informed Consent

Written informed consent was taken from all the patients before the initiation of this study.




Publikationsverlauf

Artikel online veröffentlicht:
22. August 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India